-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The edible fungus company Hualv Biology received a letter of concern from the Shenzhen Stock Exchange as a result of the high-send-to-profit distribution plan shortly after the listing on April 12th
.
On April 30, Hualv Biological responded to the letter of concern stating that this profit distribution plan did not involve speculation in stock prices, and there was no situation in which cash dividends to controlling shareholders and their affiliates would harm the interests of listed companies
On April 28th, Hualv Biological disclosed the "Announcement on the 2020 Profit Distribution and High-Send Transfer Plan".
It intends to use the company's current total share capital of 58.
35 million shares as the base, and distribute a cash dividend of 5.
2 yuan for every 10 shares, and a total cash dividend of 3034.
2 Ten thousand shares will be transferred to all shareholders from the capital reserve fund for every 10 shares, a total of 58.
35 million shares will be transferred
.
On the same day, the Shenzhen Stock Exchange issued a letter of concern to Hualv Biotech, requesting to explain the main considerations for formulating the profit distribution plan, whether the company's funds can meet the daily working capital needs after the implementation of the cash dividend, whether it will have an adverse impact on the company's production and operation, and whether There is speculation in stock prices
.
On April 30, Hualv Biological responded to the letter of concern stating that its performance has grown steadily in recent years, its cash flow is good, and its own funds are relatively abundant.
This dividend distribution will not affect normal operations
.
In addition, the company has adopted a continuous and stable cash dividend distribution policy in recent years, focusing on reasonable investment returns to investors
Hualv Biotech’s controlling shareholder and actual controller Yu Yangchao and his spouse collectively hold 39.
Hualv Biological responded that the distribution of gold dividends accounted for a small proportion of the company’s monetary capital at the end of 2020 and the company’s undistributed profits at the end of 2020.
According to data, Hualv Bio was established in 2010 and is mainly engaged in the research and development, planting and sales of edible fungi.
